Capital Impact Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Capital Impact Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-63,707	Closed	-$3.6M	–	120
2020 Q4	$3.6M	Hold	63,707	–	–	0.88%	45
2020 Q3	$3.02M	Hold	63,707	–	–	0.9%	43
2020 Q2	$3.76M	Sell	63,707 -8,560	-12%	-$476K	1.25%	16
2020 Q1	$3.42M	Buy	72,267 +4,834	+7%	+$269K	1.44%	16
2019 Q4	$4.07M	Buy	67,433 +4,999	+8%	+$298K	1.43%	11
2019 Q3	$3.69M	Buy	62,434 +38,568	+162%	+$2.51M	1.41%	11
2019 Q2	$1.54M	Hold	23,866	–	–	0.57%	107
2019 Q1	$1.23M	Hold	23,866	–	–	0.54%	105
2018 Q4	$1.23M	Hold	23,866	–	–	0.52%	108
2018 Q3	$1.24M	Hold	23,866	–	–	0.42%	117
2018 Q2	$1M	Hold	23,866	–	–	0.37%	122
2018 Q1	$1.05M	Buy	+23,866	New	+$1.21M	0.43%	121
2015 Q4	–	Sell	-5,150	Closed	-$208K	–	266
2015 Q3	$208K	Hold	5,150	–	–	0.11%	238
2015 Q2	$296K	Hold	5,150	–	–	0.13%	235
2015 Q1	$328K	Buy	+5,150	New	+$349K	0.15%	233

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Impact Advisors's IONS Position: Q1 2021 in Review

Capital Impact Advisors sold out of Ionis Pharmaceuticals (IONS) in Q1 2021, closing a stake of 63,707 shares — an estimated $3.6M sold.

Capital Impact Advisors first reported a position in IONS in Q1 2015 and held it in 15 quarters. The position peaked at $4.07M in Q4 2019. 364 funds tracked by Wall St. Rank hold IONS as of Q1 2021.

Capital Impact Advisors reported no remaining Ionis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Capital Impact Advisors sold 63,707 Ionis Pharmaceuticals shares in Q1 2021, an estimated $3.6M.
Capital Impact Advisors first reported a position in Ionis Pharmaceuticals in Q1 2015 and held it in 15 quarters.
Capital Impact Advisors's Ionis Pharmaceuticals position peaked at $4.07M in Q4 2019.
364 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2021.

Based on Capital Impact Advisors's 13F filing for Q1 2021, filed 18 May 2021.